Hengrui Pharma(SH:600276) Ge Long Hui·2025-09-05 01:11Core Viewpoint - The agreement between 恒瑞医药 and Braveheart Bio allows for the licensing of the innovative drug HRS-1893, expanding its market reach and enhancing the company's international presence [1][2] Group 1: Agreement Details - 恒瑞医药 has licensed HRS-1893 to Braveheart Bio for global development, production, and commercialization, excluding certain regions in Greater China [1] - Braveheart Bio will pay a total of $75 million, including a $65 million upfront payment and a $10 million milestone payment upon technology transfer [1] - The company is eligible for additional milestone payments related to clinical development and sales, potentially reaching up to $1.013 billion [1] Group 2: Drug Information - HRS-1893 is a Myosin selective inhibitor aimed at treating obstructive hypertrophic cardiomyopathy (oHCM) by reducing left ventricular hypertrophy and improving diastolic relaxation [1] - The drug is currently in Phase III clinical development [1] Group 3: Strategic Implications - The agreement is expected to broaden the overseas market for HRS-1893, providing quality treatment options for global patients [2] - The company aims to enhance its innovative brand and overseas performance through a combination of independent research and open collaboration [2] - By leveraging international partnerships, the company seeks to accelerate the transformation of research outcomes and maximize product value for global patients [2]